| PRECLINICAL | evidence | Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). | Semaglutide | Liver health | 2026-01-01 |
| PRECLINICAL | evidence | From Glycemic Control to Weight-Centered Therapy: A Paradigm Shift in Type 2 Diabetes and Its Public Health Promise. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Readability and understandability of online patient education on semaglutide. | Wegovy | — | 2026-01-01 |
| PRECLINICAL | evidence | Cardiovascular Outcomes and Safety of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Therapy in Older Adults with Diabetes: A Qualitative Analysis of Phase 4 ClinicalTrials.gov Studies. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Current Insights and Future Directions on the Role of GLP-1 Receptor Agonists in Chronic Kidney Disease. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs). | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Er-Chen Decoction ameliorates metabolic dysfunction-associated steatotic liver disease via gut microbiota-barrier axis-driven hepatic metabolic reprogramming. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential. | Semaglutide | Liver health | 2026-01-01 |
| PRECLINICAL | evidence | Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Oral delivery of peptides and proteins: pharmacokinetic boundaries, negative selection, and route triage. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Multi-omics profiling implicates gut microbiota-sphingolipid interplay in the neuroprotective effects of semaglutide on diabetic cognitive impairment. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Euthyroid Sick Syndrome Precipitated By Rapid Weight Loss Following Semaglutide Initiation: A Case Report. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Expert meeting report: epidemiology and management of acquired hypothalamic obesity. | Semaglutide | Weight & fat loss | 2026-01-01 |
| PRECLINICAL | evidence | Effect of Semaglutide Combined With Conventional Insulin Therapy on Blood Glucose Control and Renal Function in Elderly Patients With Type 2 Diabetes. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective. | Wegovy | — | 2026-01-01 |
| PRECLINICAL | evidence | Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Evaluating conflict-of-interest governance among Canadian medical societies using a novel assessment tool: A cross-sectional study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Quality and reliability of semaglutide content on different Chinese short video platforms: a study focusing on side effects. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Two Doses to ICU or When Lactate Equals Glucose: Life-Threatening Lactic Acidosis due to Metformin After Initiation of Semaglutide. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Decoding the hallmarks of GLP-1RA weight-loss super-responders. | Ozempic | — | 2026-01-01 |
| PRECLINICAL | evidence | Emerging Approaches for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: The Application of Nanomedicines. | Semaglutide | Inflammation | 2026-01-01 |
| PRECLINICAL | evidence | Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence. | Semaglutide | Lipid & cardiovascular markers | 2026-01-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists alleviate inflammatory responses and endothelial dysfunction in atherosclerosis by activating the Sema3A/NRP1 pathway. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Prospects for Neuroprotective Therapies in Glaucoma: Drug Targets and Emerging Clinical Strategies. | Semaglutide | Neuroprotection | 2026-01-01 |
| PRECLINICAL | evidence | Semaglutide Inhibits Osteoblast Ferroptosis Induced by Diabetic Periodontitis via Modulating the Wnt5a/Ror2/p38 MAPK Signaling Pathway. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Comparative Efficacy and Safety of Tirzepatide versus Semaglutide: A Systematic Review and Meta-Analysis with Cardiometabolic Implications. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Risk factors for drug-related impaired gastric emptying: a pharmacovigilance analysis of the FDA adverse event reporting system. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | Type B insulin resistance with glycemic extremes: a case report and literature review. | Semaglutide | Glycemic control | 2026-01-01 |
| PRECLINICAL | evidence | Risk Factors for Hypoglycemia in Type 2 Diabetes Mellitus Patients Using Once-Weekly Semaglutide: A Matched Case-Control Study. | Semaglutide | — | 2026-01-01 |
| PRECLINICAL | evidence | [Pharmacological treatment of obstructive sleep apnea syndrome]. | Semaglutide | Sleep quality | 2026-01-01 |